Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Discontinued
Reference number: GID-TA10926
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following an update from the company that market venetoclax, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.
If you have any comments or concerns, please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)